Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d; "We are very pleased to enter this partnership with ThromboGenics and BioInvent. This novel antibody, TB-403 has the potential to play a major role in the treatment of cancer and we are committed to driving ahead with its development. In addition, we look forward to developing a strong working relationship with ThromboGenics and BioInvent."

Notes to Editors:

About TB-403

TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB) at the University of Leuven, Belgium, where the therapeutic potential of anti-PlGF agents to treat cancer was first developed in the laboratory of Prof. Peter Carmeliet.

Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutrients. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. PlGF is a homologue of VEGF and current preclinical evidence suggests that it may not affect normal, physiological angiogenesis and is predominantly involved in angiogenesis of malignant tissue.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF). ThromboGenics and BioInvent have recently signed a license agreement with Roche for TB-403 worth EUR 500 million plus royalties. TB-403 is scheduled to enter a Phase Ib clinical t
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
(Date:9/22/2014)... This is a professional and in-depth ... industry in Global and China. The report provides ... and industry chain structure. Global market analysis and Chinese ... history, developments, trends and competitive landscape of the market. ... also offered. , The report also focuses on development ...
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 ... desire to stay young has groomed and nurtured ... industry worldwide. Growing emphasis on appearance maintenance is ... is a neurotoxic protein obtained from the bacterium, ... resulting in muscle relaxation. With cosmetic indications for ...
Breaking Biology Technology:Graphene imperfections key to creating hypersensitive 'electronic nose' 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3
... Austria, May 27 The atherosclerosis vaccine,development program ... the,EU,s EUROTRANS-BIO call. The respective project is being ... GmbH. The aim of,atherosclerosis vaccination is to increase ... in the blood and thus reduce the occurrence ...
... Efficiency and Manage Quality at New LIFE Nutrition Factory ... (NYSE: HON ) today announced that it ... manufacturer of healthcare products, to provide process control solutions ... and infusion therapy solutions. The Leading Infusion Factory Europe ...
... SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... previously announced sale of 3,878,993 shares of its common stock ... for gross proceeds of approximately $11.1 million on May 26, ... unit (each unit consisting of one share and a warrant ...
Cached Biology Technology:AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4Oncothyreon announces closing of $11.1 million registered direct financing 2
(Date:9/23/2014)... consumption could be as good for your mental as ... conducted by the University of Warwick,s Medical School using ... by BMJ Open focused on mental wellbeing ... consistently associated with an individual,s fruit and vegetable consumption. ... five or more portions of fruit and vegetables a ...
(Date:9/23/2014)... including humans, have parasitic DNA fragments called "jumping genes" ... in the process. And that phenomenon can result in ... University of Rochester now report that the "jumping genes" ... a multi-function protein stops keeping them in check in ... a study published today in Nature Communications , ...
(Date:9/22/2014)... STATION The smell of cut grass in recent ... signalling distress, but new research says the aroma also ... is need for protection, the plant signals the environment ... recognized as a feeding queue for parasitic wasps to ... lay eggs in the pest insect," said Dr. Michael ...
Breaking Biology News(10 mins):Eating five a day may keep the blues away 2A multi-function protein is key to stopping genomic parasites from 'jumping' 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... This release is available in Spanish . ... Medical Research (CIMA) of the University of Navarra has identified ... enzyme is involved in the accumulation of fibrous tissues in ... of heart functions. The research project, published in the ...
... April 21 More than 3,200 items of ... be displayed during the 2009 Force Protection Equipment ... VA, and Marine Corps Base, Quantico, VA, during ... of Defense, personnel with physical security responsibilities in ...
... losses and the environmental impact caused by invasive species ... alone. An example of this is the zebra mussel, ... to a New York Sea Grant report. In ... species, the armored catfish, or plecostomus, in the Infiernillo ...
Cached Biology News:Researchers identify a molecule that increases the risk of cardiac insufficiency 2Combating Terrorism with Commercial Technology: 2009 Force Protection Equipment Demonstration 2North America works to halt invasive species 2
ECE-1 (H-60)...
... to Neuron navigator 1 ( Abpromise for ... Synthetic peptide conjugated to KLH derived from within ... navigator 1. (Note: the amino acid sequence ... ab32208 .) Entrez Gene ...
Rac 1/2/3/4 (S-18)...
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Biology Products: